Although the risk of progression from monoclonal B-cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) has been well characterized, it is unknown whether other common complications associated with CLL, such as increased risk of infection, occurs in individuals with MBL. We used the Mayo CLL database to identify cohorts of individuals with newly diagnosed MBL (n ¼ 154) or newly diagnosed CLL (n ¼ 174) who resided within 50 miles of Mayo Clinic. A cohort of 689 adult patients seen for a general medical examination who resided within 50 miles of Mayo clinic and who enrolled in a case-control study of non-Hodgkin lymphoma (NHL) was used as a comparison cohort. Hospitalization with infection was more common among individuals with MBL (25/154; 16.2%), and CLL (32/174; 18.4%) than controls (18/689; 2.6%). On pooled multivariable Cox proportional hazards analysis of all 1017 patients (controls, MBL and CLL), male sex (hazards ratio (HR) ¼ 2.3; P ¼ 0.002), major co-morbid health problems (HR ¼ 1.7, P ¼ 0.04), the presence of CLL (HR ¼ 3.2, Po0.001), treatment for progressive CLL (HR ¼ 2.4, P ¼ 0.001) and the presence of MBL (HR ¼ 3.0, P ¼ 0.001) were independently associated with risk of hospitalization for infection. These results suggest the risk of serious infection in clinical MBL is substantially greater than the risk of progression requiring treatment.
INTRODUCTION
Monoclonal B-cell Lymphocytosis (MBL) is an asymptomatic condition characterized by the presence of a small (o5 Â 10 9 /l) population of clonal B cells in the peripheral blood in the absence of lymphadenopathy, cytopenias or autoimmune disease. 1, 2 The immunophenotype of the B-cell clone in most individuals with MBL is identical to chronic lymphocytic leukemia (CLL), but clones with the phenotype of other non-Hodgkin lymphoma (NHL) subtypes can also occur. 3, 4 Although screening studies indicate that 3-12% of the general population over age 40 has MBL, only a fraction of these MBL cases come to clinical attention (clinical MBL), typically when patients undergo evaluation for mild lymphocytosis. 2, 5 Multiple studies have now demonstrated that the risk of progression from clinical MBL to CLL requiring chemotherapy treatment is B1%/year. 6, 7 Although the risk of progression from MBL to CLL has been well characterized, it is unknown whether other complications associated with CLL also occur in individuals with MBL. Infections are one major cause of morbidity and mortality in patients with CLL. 8 Up to 50% of patients with CLL will develop infectious complications during the course of their disease, and 30-50% of all deaths in patients with CLL are attributed to infections or infectious complications. 9 Whether individuals with MBL are at greater risk for infection than the general population is unknown. Studies indicate that a history of infection may be a risk factor for developing CLL, [10] [11] [12] suggesting that individuals with MBL may be at greater risk for infection and/or that infection could relate to the risk of progression among individuals with MBL. We evaluated the rates of hospitalization for infection in locally dwelling cohorts of individuals with newly diagnosed clinical MBL and CLL as well as a cohort of locally dwelling patients presenting for a general medical exam who agreed to participate in a prospective case-control study of NHL.
MATERIALS AND METHODS Patients
With the approval of the Mayo Clinic Institutional Review Board and in accord with federal regulations and the Declaration of Helsinki, we used the Mayo Clinic CLL Database to identify all patients with a new diagnosis of CLL or MBL between 1 January 1999 and 31 December 2009. The Mayo Clinic CLL Database includes all patients with a diagnosis of CLL seen in the Division of Hematology at Mayo Clinic who permit their records to be used for research purposes. Clinical information regarding date of diagnosis, treatment history and disease-related complications is abstracted from clinical records on all patients and then maintained prospectively.
Since the purpose of this study was to focus on local, non-referred patients, analysis was limited to patients whose residence was within 50 miles of Mayo Clinic Rochester. Mayo Clinic is the primary hematology center for most of this region and Mayo Clinic hospitals are the only hospitals within 40 miles with the exception of 1 community hospital (Olmsted Medical Center; 61 beds) primarily used by individuals who are not Mayo Clinic patients.
The control cohort consisted of 689 adult patients residing within 50 miles of Mayo Clinic seen for a pre-scheduled general medical examination between September 2002 and December 2009 and who were enrolled as controls in a case-control study of NHL (see Cerhan et al. 13 for detailed description). All controls were aged 18 þ and had no prior diagnosis of leukemia, lymphoma or HIV.
Hospitalization for infection
Hospitalizations for infections were identified in two ways:
(1) The electronic Mayo Clinic infection database was used to identify all positive culture results among local, non-referred CLL, MBL and controls patients. This database includes all culture results obtained from Mayo Clinic patients associated with hospitalization since 1999. The infection database also includes direct antigen detection (for example, Cryptococcus antigen, Aspergillus antigen) and blood-based viral PCR testing (for example, cytomegalovirus viral load) results dating to 2004. Hospitalized patients who had a culture from a sterile site (for example, blood, cerebrospinal fluid, pleural fluid or paracentesis fluid) or sputum which grew staphylococcal species (other than Staphylococcus epidermidis), Streptococcal pneumonia, E. coli, Klebsiella species, Pseudomonal species, Haemophilus influenza, Nocardia species, Mycobacterium species, Pneumocystic jiroveci and Aspergillus species were considered to have documented infection. In addition, hospitalized patients who had a positive Cryptococcus antigen testing in the blood or cytomegalovirus viremia documented in the blood by PCR were also considered to have documented infection. To determine whether positive cultures represented clinical infection rather than colonization/contamination, electronic records from all hospitalizations were reviewed to identify whether a clinical diagnosis of infection was made, whether antibiotics were administered, and the duration of the antibiotic course. Patients who had a clinical diagnosis of infection and who received at least a 5-day course of antibiotics were considered to have a documented infection while those with positive cultures who did not receive at least a 5-day course of antibiotics or have a clinical diagnosis of an infection were considered to represent contamination/colonization.
(2) Hospitalizations with infection among patients who did not have positive cultures were identified by reviewing the discharge summary of all patient hospitalizations. Patients with both (i) a clinical diagnosis of infection (for example, pneumonia) and (ii) who were treated clinically with at least a 5-day course of antibiotic treatment were considered to have a 'culture negative' infection.
As a quality measure to identify hospitalizations at non-Mayo hospitals, we also surveyed the 244 living CLL/MBL patients in September 2010. The survey asked patients (1) whether they had been hospitalized for infection since their CLL/MBL diagnosis (and at which hospital), (2) how many times they had been hospitalized with infection and (3) site of infection. Infections ascertained in this way were not included in the primary analysis but were used to assess the accuracy of hospitalizations at Mayo hospitals as a proxy for all hospitalizations in these locally dwelling patient cohorts.
Co-morbid health conditions
Data on co-morbid health problems at the time of CLL diagnosis or consent date (for controls) were abstracted from clinical records at Mayo in a manner similar to our previously published approach. 14 
Statistical methods
Descriptive statistics were computed for each cohort. Chi-square or Fisher's exact statistics measured the association between infection status and possible explanatory variables; odds ratios and 95% confidence intervals (CIs) are reported. The incidence of hospitalization with infection was calculated as the number of observed infections divided by the number of person years at risk per each sex-and 10 year age-strata. Person years were defined from diagnosis or consent date (controls) until the date of first infection, death or last known alive. The standardized incidence ratios (SIRs) and 95% CIs 15 for MBLs and then for CLLs were calculated as the ratio of the observed to the expected number of infections. The expected numbers were derived from the age-and sex-adjusted control rates.
Estimates of survival free of hospitalization for each cohort (MBL, CLL and controls) were calculated and plotted using the Kaplan-Meier method. In a secondary sensitivity analyses, we censored cases at the initiation of treatment for progressive CLL. The cohorts were combined for multivariable Cox proportional hazards modeling adjusting for age, gender, the presence of major co-morbid health problems, the presence of MBL, the presence of CLL, and whether or not patients received treatment for CLL during follow-up were employed to determine characteristics associated with hospitalization to estimate hazards ratios (HRs) and 95% CIs for risk of hospitalization with infections. Statistical tests were two-sided, and P-values of o0.05 were considered significant.
RESULTS

Descriptive results
We identified 328 individuals who were newly diagnosed with clinically identified MBL (n ¼ 154) or CLL (n ¼ 174) between 1 January 1999 and 31 December 2009 and who resided within 50 miles of Mayo Clinic; controls were 689 individuals residing within 50 miles of Mayo being seen for a pre-scheduled general medical evaluation between 1 September 2002 and 31 December 2009 and who consented to participate as controls in a casecontrol study of NHL. 13 Patients with CLL (median age 69) and MBL (median 70) were older than the control population (median age 60) and were more likely to be male. Consistent with their older age, patients in the CLL and MBL cohorts also had a somewhat higher prevalence of co-morbid health conditions ( Table 1) .
The median follow-up for individuals with MBL (median 4.1 years; range 0.2-10.3) and CLL (median ¼ 4.0 years; range 0-10.9) was slightly longer than controls (median 3.0 years; range 0-5.8).
In unadjusted analysis, hospitalization with infection was more common among individuals with MBL (25/154; 16.2%), and CLL (32/174; 18.4%) than controls (18/689; 2.6%, Figure 1a ). Among patients hospitalized with infection, 18 patients died before discharge (control ¼ 1, MBL ¼ 3, CLL ¼ 14), suggesting that infection may have contributed to death in 0.1% (1/689) of controls, 1.9% (3/154) of MBLs and 8.0% (14/174) of CLL patients (Po0.001). Patients with CLL and MBL remained at higher risk of hospitalization for infection when analysis was limited to hospitalizations for infection that occurred before receiving chemotherapy treatment for progressive CLL (Figure 1b) .
Among patients with MBL and CLL who were hospitalized with infection, the median number of hospitalizations with infections were similar (MBL median ¼ 1, range 1-8; CLL median ¼ 1, range 1-13, P ¼ 0.11). Information on the site of infection and the infectious organisms identified are shown in Table 2 . Infections with Gram-positive organisms were more common among individuals with CLL and MBL relative to controls. Novel infections and those more directly correlating with immunosuppression (for example, invasive aspergillosis, nocardiosis, cytomegalovirus, P. jiroveci) occurred in 2.9% (5/174) of patients with CLL and 0.6% (1/154) of patients with MBL, but these infections all occurred after receiving treatment in progressive patients.
Treatment for progressive MBL or CLL was strongly associated with an increased risk of hospitalization with infection (HR ¼ 3.1, 95% CI ¼ 1.7-5.6; Po0.001). Among the 101 patients with CLL or MBL that progressed to require treatment, B30% had been hospitalized with infection within 4 years of starting treatment (Figure 2 ). Time to hospitalization for infection was also significantly shorter among patients who had any major co-morbidity (HR ¼ 1.8, 95% CI ¼ 1.1-3.0; P ¼ 0.02) or a history of stroke (HR ¼ 3.4, 95% CI ¼ 1.7-6.9; P ¼ 0.0007), diabetes mellitus (HR ¼ 2.3, 95% CI ¼ 1.2-4.1; P ¼ 0.008), hypertension (HR ¼ 1.7, 95% CI ¼ 1.1-2.8; P ¼ 0.02) or psychiatric illness (HR ¼ 1.9, 95% CI ¼ 1.1-3.2; P ¼ 0.03) specifically, regardless of whether or not they had MBL or CLL.
Excess risk of infection Age-and sex-adjusted SIRs and 95% CIs showed that both MBL and CLL patients were at higher risk of infection compared with controls on adjusted analysis. Among MBLs, we observed 25 infections when only 10 were expected (SIR ¼ 2.5, 95% CI ¼ 1.6-3.7). Similarly, among CLLs, we observed 32 infections when only 12 were expected (SIR ¼ 2.6, 95% CI ¼ 1.8-3.7).
We next conducted a pooled multivariable Cox proportional hazards analysis of all 1017 patients (controls, MBL and CLL) to identify factors independently associated with time to hospitalization for infection adjusting for age, gender, the presence of major co-morbid health problems, the presence of MBL, the presence of CLL, and whether or not patients received treatment for CLL during follow-up. Male sex (HR ¼ 2.3, 95% CI ¼ 1.4-4.0; P ¼ 0.002), major co-morbid health problems (HR ¼ 1.7, 95% CI ¼ 1.03-2.8; P ¼ 0.04), the presence of CLL (HR ¼ 3.2, 95% CI ¼ 1.6-6.4; Po0.001) and treatment for progressive CLL (HR ¼ 2.4, 95% CI ¼ 1.4-4.1; P ¼ 0.001) were all independently associated with time to hospitalization for infection, as was the presence of MBL (HR ¼ 3.0, 95% CI ¼ 1.5-6.0; P ¼ 0.001) after controlling for all other factors.
Measures of immune function
Next, we explored the association between clinically available measures of immune function (gamma-globulin levels, T-cell counts and NK cell counts) and infection risk among patients with CLL and MBL. Median gamma-globulin levels and T-cell/NK cell counts at diagnosis are shown in Table 3 . At the time of diagnosis, only 1.0% (1/100) of MBL patients and 3.5% (5/144) of CLL patients had hypogammaglobulinemia (for example, IgG level o500 mg/dl). Among patients with IgG levels measured within 12 months of diagnosis, no statistically significant association between IgG levels (either as continuous variable or as normal vs. deficient) and hospitalization for infection was observed. Absolute T-cell count and NK cell count at diagnosis were not associated with subsequent risk of hospitalization for infection.
Survey to assess completeness of ascertainment of hospitalizations for infection Since our ascertainment of hospitalization with infection was limited to Mayo Clinic Hospitals, we also surveyed CLL/MBL patients to identify hospitalization for infection at other facilities. Of the 96/115 (83%) MBL patients who returned surveys, 6 (6%) reported that they had been hospitalized for an infection at a non-Mayo hospital since their MBL diagnosis. Of the 108/123 (88%) CLL patients who returned surveys, 10 (9%) reported that they had been hospitalized for an infection at a non-Mayo hospital since their CLL diagnosis. Of these, 2/6 (33%) MBL and 3/10 (30%) CLL also had at least 1 hospitalization for infection at Mayo hospitals. Thus considering both audit of Mayo records and selfreported rate of hospitalizations at non-Mayo hospitals, the rate of hospitalization for infection among MBL and CLL patients would increase by B2.5% and 4%, respectively. The impact among controls is not known. 42 (6) 24 (16) 13 (8) 0.0004 Respiratory (COPD)
71 (10) 24 (16) 23 (13) 0.14 Malignancy prior 51 (7) 24 (16) 20 (12) Although the rate of progression from clinical MBL to CLL requiring treatment is well described, 6, 7, 16 other clinical consequences of MBL have not been well defined. Here, we find that individuals with newly diagnosed clinical MBL are at B3-fold higher risk of hospitalization with infection after adjusting for age, sex and co-morbid health conditions, compared with a control population of adults undergoing for a pre-scheduled general medical exam. After a median of 4 year follow-up from diagnosis, the rate of hospitalization for infection in MBL patients (B16%) is roughly fourfold greater than the risk of progression to CLL requiring treatment, 6, 7 suggesting that patients with MBL are at greater risk of infectious complications than they are progression.
The rates of hospitalization with infection among individuals with MBL were slightly lower than that of patients with newly diagnosed CLL. Much of this difference appeared due to a heightened risk of infection in the subset of CLL patients who progressed to require treatment. On multivariable analysis adjusting for treatment, the risk of hospitalization with infection among patients with MBL and CLL was similar (both HRs B3). Even before receiving treatment, however, individuals with MBL or CLL were at greater risk of hospitalization with infection relative to controls (Figure 1) . The increased susceptibility to infection among patients with CLL is known to be in part related to immune deficiencies such as hypogammaglobulinemia and defects in T-cell function. 8, 9, 17 Hypogammaglobulinemia, however, was not the basis of increased risk of infection among patients with MBL or newly diagnosed CLL in our study since, consistent with previous reports, 18 very few of the newly diagnosed individuals in our MBL or CLL cohorts had hypogammaglobulinemia.
These observations suggest that the presence of MBL may be a marker of a less competent immune system and raise a number of important questions. Are individuals with MBL also at risk for some of the other complications associated with CLL (for example, higher risk of skin cancers, 19, 20 higher risk of second malignancies [20] [21] [22] and autoimmune cytopenias 23 )? Should immunization strategies or other preventive health recommendations for individuals with MBL differ from the general public (for example, pneumococcal vaccination at diagnosis independent of age; avoidance of live attenuated vaccines)? Since co-morbidities were an independent risk factor for infection, an interaction between MBL and co-morbid health conditions is also possible (for example, co-existence of MBL with certain co-morbidities makes an individual particular sensitive to infection). Additional studies are needed however to address these questions.
It should be emphasized that our analysis focuses on patients with clinically identified MBL. 2, 5 Since population screening for MBL is not current practice, clinically identified MBL is the type of MBL that physicians encounter in routine practice and represent the individuals in need of counseling and disease management. In this respect, our cohort represents the most clinically relevant form of MBL for study. If the association between infection and clinical MBL also holds true for patients with MBL identified on population screening, then it would raise a host of different and critically important questions at the public health/population level since 3-12% of individuals over the age of 40 have MBL on screening studies. 3, 4, 24 Our study is subject to a number of limitations. First, our MBL and CLL cohorts represent clinical cohorts (for example, patients seen in division of hematology during a defined time frame) rather than a population-based sample. Although Mayo Clinic is a tertiary referral center, it is located in a largely rural area in southeastern Minnesota and is the primary hematology center for the large surrounding region of southeastern Minnesota. By limiting our analysis to patients residing within a 50 mile radius of Mayo Clinic, our results should generalize to community-based patients with CLL and MBL rather than referred patients, at least for white patients. Further, the rates of hospitalization for infection among our CLL cohort and the distribution of bacterial, viral and fungal infections were nearly identical to those in a cohort of 280 consecutively diagnosed CLL patients at Birmingham Heartland's Hospital 9 further enhancing the validity or our finding (the latter study did not have comparable data on MBL or controls).
Second, we used controls recruited through the general internal medicine clinic at Mayo and who were from the same region as the MBL and CLL cases. This is the most appropriate methodologic approach for comparison with clinically ascertained MBL and CLL patients seen at Mayo, since selection of population-based controls could introduce bias related to use and access to medical care. 13 Controls were drawn from patients presenting for prescheduled general medical examinations, to avoid introducing a selection bias based on any specific active diagnosis. We also did not exclude controls with a history of other medical conditions, ensuring that the controls were representative of the underlying population that generated the cases.
Third and importantly for this analysis, our study focused on hospitalizations with infection that occurred at Mayo Clinic hospitals in Rochester, MN for whom accurate distinction between infection and contamination could be made. Mayo hospitals (2059 beds) are the only hospitals within 50 miles with the exception of 1 community hospital in Rochester (61 beds) primarily used by individuals who are not Mayo Clinic patients and two small regional hospitals (41 and 48 miles away; 99 and 134 beds, respectively). Although hospitalization of patients at other facilities or while traveling would not be ascertained by this approach, this limitation was consistent across all three cohorts. Based on patient surveys, few patients reported hospitalization at non-Mayo hospitals suggesting such events would not alter the overall interpretation of our current findings.
In summary, individuals with clinically identified MBL appear to be at higher risk of developing serious infection. The risk of serious infection among individuals with MBL appears substantially greater than their risk of progression to CLL requiring treatment. Additional studies are needed to better define the optimal care of patients with MBL (for example, vaccination strategies), the biologic basis of their susceptibility to infection, and whether the increased risk of infection also occurs in MBL identified on population screening. Infectious complications among individuals with clinical MBL J Moreira et al
